Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients
Gespeichert in:
Veröffentlicht in: | Annals of hematology 2021-04, Vol.100 (4), p.1111-1113 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1113 |
---|---|
container_issue | 4 |
container_start_page | 1111 |
container_title | Annals of hematology |
container_volume | 100 |
creator | Zappasodi, P. Brociner, M. Merati, G. Nizzoli, M. E. Roncoroni, E. Boveri, E. Castagnola, C. Arcaini, L. |
description | |
doi_str_mv | 10.1007/s00277-020-04333-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2501357946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2501357946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-2116230b091ba3f1c471119695dee1d8f2cc44d6cec017d7d154660fc01d8d763</originalsourceid><addsrcrecordid>eNp9kM1u1TAQhS0EoreFF2CBLLFOO_5JnCxRRQGpEhtgazn25MolsYPtIMIr8NK43AI7ZuMZzZlz5I-QFwwuGYC6ygBcqQY4NCCFEI16RA5MCt5A28vH5ACDGJq21hk5z_kOgPFe8qfkTAimWjb0B_LzMwYs0c7mOzXBUfPD2L145wNSG5fRB1N8DNTnuqY4TWiL_4Z0TN4dkZZISzIhr7MJhebaFzzu1AeacDZrRneVcErGlph2auxWkC47ztE7OuP2BRdv6FojMJT8jDyZzJzx-cN7QT7dvPl4_a65_fD2_fXr28YKyUvDGeu4gBEGNhoxMSsVY2zohtYhMtdP3FopXWfRAlNOOdbKroOpTq53qhMX5NXJd03x64a56Lu4pVAjNW-BiVYN8l7FTyqbYs71F3pNfjFp1wz0PX994q8rf_2bv1b16OWD9TYu6P6e_AFeBeIkyHUVjpj-Zf_H9hedN5NV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501357946</pqid></control><display><type>article</type><title>Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Zappasodi, P. ; Brociner, M. ; Merati, G. ; Nizzoli, M. E. ; Roncoroni, E. ; Boveri, E. ; Castagnola, C. ; Arcaini, L.</creator><creatorcontrib>Zappasodi, P. ; Brociner, M. ; Merati, G. ; Nizzoli, M. E. ; Roncoroni, E. ; Boveri, E. ; Castagnola, C. ; Arcaini, L.</creatorcontrib><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-020-04333-7</identifier><identifier>PMID: 33175198</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - toxicity ; Azacitidine - therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use ; Female ; Hematology ; Humans ; Letter to the Editor ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Sulfonamides - therapeutic use</subject><ispartof>Annals of hematology, 2021-04, Vol.100 (4), p.1111-1113</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-2116230b091ba3f1c471119695dee1d8f2cc44d6cec017d7d154660fc01d8d763</citedby><cites>FETCH-LOGICAL-c342t-2116230b091ba3f1c471119695dee1d8f2cc44d6cec017d7d154660fc01d8d763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-020-04333-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-020-04333-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33175198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zappasodi, P.</creatorcontrib><creatorcontrib>Brociner, M.</creatorcontrib><creatorcontrib>Merati, G.</creatorcontrib><creatorcontrib>Nizzoli, M. E.</creatorcontrib><creatorcontrib>Roncoroni, E.</creatorcontrib><creatorcontrib>Boveri, E.</creatorcontrib><creatorcontrib>Castagnola, C.</creatorcontrib><creatorcontrib>Arcaini, L.</creatorcontrib><title>Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - toxicity</subject><subject>Azacitidine - therapeutic use</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Sulfonamides - therapeutic use</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kM1u1TAQhS0EoreFF2CBLLFOO_5JnCxRRQGpEhtgazn25MolsYPtIMIr8NK43AI7ZuMZzZlz5I-QFwwuGYC6ygBcqQY4NCCFEI16RA5MCt5A28vH5ACDGJq21hk5z_kOgPFe8qfkTAimWjb0B_LzMwYs0c7mOzXBUfPD2L145wNSG5fRB1N8DNTnuqY4TWiL_4Z0TN4dkZZISzIhr7MJhebaFzzu1AeacDZrRneVcErGlph2auxWkC47ztE7OuP2BRdv6FojMJT8jDyZzJzx-cN7QT7dvPl4_a65_fD2_fXr28YKyUvDGeu4gBEGNhoxMSsVY2zohtYhMtdP3FopXWfRAlNOOdbKroOpTq53qhMX5NXJd03x64a56Lu4pVAjNW-BiVYN8l7FTyqbYs71F3pNfjFp1wz0PX994q8rf_2bv1b16OWD9TYu6P6e_AFeBeIkyHUVjpj-Zf_H9hedN5NV</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Zappasodi, P.</creator><creator>Brociner, M.</creator><creator>Merati, G.</creator><creator>Nizzoli, M. E.</creator><creator>Roncoroni, E.</creator><creator>Boveri, E.</creator><creator>Castagnola, C.</creator><creator>Arcaini, L.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20210401</creationdate><title>Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients</title><author>Zappasodi, P. ; Brociner, M. ; Merati, G. ; Nizzoli, M. E. ; Roncoroni, E. ; Boveri, E. ; Castagnola, C. ; Arcaini, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-2116230b091ba3f1c471119695dee1d8f2cc44d6cec017d7d154660fc01d8d763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - toxicity</topic><topic>Azacitidine - therapeutic use</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Sulfonamides - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zappasodi, P.</creatorcontrib><creatorcontrib>Brociner, M.</creatorcontrib><creatorcontrib>Merati, G.</creatorcontrib><creatorcontrib>Nizzoli, M. E.</creatorcontrib><creatorcontrib>Roncoroni, E.</creatorcontrib><creatorcontrib>Boveri, E.</creatorcontrib><creatorcontrib>Castagnola, C.</creatorcontrib><creatorcontrib>Arcaini, L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zappasodi, P.</au><au>Brociner, M.</au><au>Merati, G.</au><au>Nizzoli, M. E.</au><au>Roncoroni, E.</au><au>Boveri, E.</au><au>Castagnola, C.</au><au>Arcaini, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>100</volume><issue>4</issue><spage>1111</spage><epage>1113</epage><pages>1111-1113</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33175198</pmid><doi>10.1007/s00277-020-04333-7</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0939-5555 |
ispartof | Annals of hematology, 2021-04, Vol.100 (4), p.1111-1113 |
issn | 0939-5555 1432-0584 |
language | eng |
recordid | cdi_proquest_journals_2501357946 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antineoplastic Combined Chemotherapy Protocols - toxicity Azacitidine - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Female Hematology Humans Letter to the Editor Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Male Medicine Medicine & Public Health Middle Aged Oncology Sulfonamides - therapeutic use |
title | Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T16%3A43%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Venetoclax%20and%20azacytidine%20combination%20is%20an%20effective%20bridge%20to%20transplant%20strategy%20in%20relapsed/refractory%20acute%20myeloid%20leukemia%20patients&rft.jtitle=Annals%20of%20hematology&rft.au=Zappasodi,%20P.&rft.date=2021-04-01&rft.volume=100&rft.issue=4&rft.spage=1111&rft.epage=1113&rft.pages=1111-1113&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-020-04333-7&rft_dat=%3Cproquest_cross%3E2501357946%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501357946&rft_id=info:pmid/33175198&rfr_iscdi=true |